GLP-1受体激动剂与糖尿病足重建术后结局的倾向评分匹配回顾性队列研究
本研究基于TriNetX数据库,纳入2016年1月至2025年2月因足部溃疡行软组织重建的糖尿病成人患者,按GLP-1受体激动剂使用史分层并行1:1倾向评分匹配。匹配后每组各1049例,GLP-1 RA使用者90天手术部位感染、翻修手术、深静脉血栓、急诊就诊及全因死亡率均较低,而伤口裂开、肺栓塞、脓毒症和截肢率无显著差异。
要点
- GLP-1 RA使用与糖尿病足软组织重建后90天手术部位感染率降低相关(4.6% vs. 7.3%)。
- GLP-1 RA使用与翻修手术、深静脉血栓、急诊就诊及全因死亡率降低相关。
- 伤口裂开、肺栓塞、脓毒症和截肢率在两组间无显著差异。
核心结论
- 糖尿病足软组织重建患者中,GLP-1 RA使用与较低的90天手术部位感染、翻修手术、深静脉血栓、急诊就诊及全因死亡率相关。
- 提示GLP-1 RA可能独立于代谢效应对手术恢复具有潜在保护作用,但需前瞻性和实验性研究明确机制及完整影响。
研究设计与样本
- 倾向评分匹配回顾性队列研究,使用TriNetX数据库。
- 纳入2016年1月至2025年2月因足部溃疡行软组织重建的糖尿病成人患者,按GLP-1 RA使用史分层。
- 基于人口学、合并症、体重指数和糖化血红蛋白进行1:1倾向评分匹配,匹配后每组各1049例。
- 比较90天术后结局的风险比。
主要发现
- GLP-1 RA使用者90天手术部位感染率为4.6%,非使用者为7.3%(p<0.05)。
- GLP-1 RA使用者翻修手术率为3.7%,非使用者为6.3%(p<0.05)。
- GLP-1 RA使用者深静脉血栓率为2.1%,非使用者为5.0%(p<0.05)。
- GLP-1 RA使用者急诊就诊率为19.2%,非使用者为23.0%(p<0.05)。
- GLP-1 RA使用者全因死亡率为2.4%,非使用者为4.6%(p<0.05);伤口裂开、肺栓塞、脓毒症和截肢率无显著差异(p>0.05)。
临床怎么用
- 在糖尿病足软组织重建围手术期评估中,可将GLP-1 RA使用史作为术后并发症风险分层的参考因素。
- 对使用GLP-1 RA的患者,仍需按常规监测伤口裂开、肺栓塞、脓毒症和截肢等无显著差异的结局。
局限性
- 回顾性队列研究设计,仅能提示关联而非因果关系。
- 需前瞻性和实验性研究明确GLP-1 RA对手术结局的作用机制及完整影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to evaluate the association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and surgical outcomes, complications, and healthcare utilization in diabetic patients undergoing soft-tissue reconstruction for foot ulcers. METHODS: The TriNetX database was used to identify diabetic adult patients who underwent soft-tissue reconstruction for foot ulcers between January 2016 and February 2025. Cohorts were stratified by the history of GLP-1 RA use. A 1:1 propensity score matching was performed based on demographics, comorbidities, body mass index, and hemoglobin A1c. Risk ratios were compared for 90-day postoperative outcomes. RESULTS: After PSM, 1049 patients were included in each of the cohorts. GLP-1 RA users had lower 90-day rates of surgical-site infections (SSIs; 4.6% vs. 7.3%), revision surgery (3.7% vs. 6.3%), deep vein thrombosis (DVT; 2.1% vs. 5.0%), emergency department (ED) utilization (19.2% vs. 23.0%), and all-cause mortality (2.4% vs. 4.6%; all p<0.05) compared to nonusers. No significant differences were observed for wound dehiscence, pulmonary embolism, sepsis, and amputation rates (p>0.05). CONCLUSION: GLP-1 RA use in diabetic patients undergoing soft-tissue reconstruction for foot ulcers was associated with lower rates of SSIs, surgical revisions, DVT, ED utilization, and all-cause mortality compared to nonusers. These findings suggest a potential protective role of GLP-1 RA in surgical recovery independent of metabolic effects. Prospective and experimental investigation is needed to clarify the mechanism and full impact of GLP-1 RA on surgical outcomes.
引用
- Zhang JZ, Khong J, Suresh R, et al. GLP-1 receptor agonist use and surgical outcomes following diabetic foot reconstruction: A propensity score-matched retrospective cohort study. J Plast Reconstr Aesthet Surg. 2026. PMID: 41880708. doi:10.1016/j.bjps.2026.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。